Prognostic significance of pituitary tumour-transforming gene-binding factor (PBF) expression in papillary thyroid carcinoma
Summary Background Pituitary tumour‐transforming gene (PTTG)‐binding factor (PBF), originally known as PTTG1 interacting protein (PTTG1IP), has been found to be significantly increased in well‐differentiated thyroid cancer and independently associated with early tumour recurrence. Objective To asses...
Saved in:
| Published in | Clinical endocrinology (Oxford) Vol. 78; no. 2; pp. 303 - 309 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford
Blackwell Publishing Ltd
01.02.2013
Blackwell Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0300-0664 1365-2265 1365-2265 |
| DOI | 10.1111/cen.12007 |
Cover
Loading…
| Abstract | Summary
Background
Pituitary tumour‐transforming gene (PTTG)‐binding factor (PBF), originally known as PTTG1 interacting protein (PTTG1IP), has been found to be significantly increased in well‐differentiated thyroid cancer and independently associated with early tumour recurrence.
Objective
To assess the prognostic significance of PBF expression in a large cohort of papillary thyroid carcinoma (PTC) patients with a long‐term follow‐up.
Design and patients
Retrospective analysis of PBF expression in PTC cases at different stages and correlate it with various clinicopathological parameters and patient survival. Subjects included 153 patients who received a thyroid operation for PTC at Chang Gung Memorial Hospital between 1991 and 2000. All patients had a complete follow‐up till the end of 2010.
Measurements
Immunohistochemical study for PBF expression on tissue sections from tumour specimens. Bond automated machine (Leica Microsystems, Germany) with a polyclonal rabbit anti‐PBF antibody (LifeSpan BioSciences, LS‐C118942, Seattle, WA, USA) was used. SPSS 13.0 for Windows (SPSS Inc, Chicago, IL, USA) was used for all statistical analyses.
Results
High PBF expression was significantly correlated with age (P = 0·0298), distant metastases at diagnosis (P = 0·0139), tumour multicentricity (P = 0·0035), TNM stage (P = 0·0103), locoregional recurrence (P = 0·0410) and disease‐specific mortality (P = 0·0064). The expression level of PBF was significantly correlated with disease‐specific survival (P = 0·0065). Cox regression analysis showed that age, tumour size and PBF expression were independent prognostic indicators (P = 0·0097, P = 0·0021 and P = 0·0179).
Conclusion
PBF expression may be a promising biomarker for prognostic and therapeutic purpose. More large‐scale studies are needed to clarify its potential usefulness. |
|---|---|
| AbstractList | Pituitary tumour-transforming gene (PTTG)-binding factor (PBF), originally known as PTTG1 interacting protein (PTTG1IP), has been found to be significantly increased in well-differentiated thyroid cancer and independently associated with early tumour recurrence. To assess the prognostic significance of PBF expression in a large cohort of papillary thyroid carcinoma (PTC) patients with a long-term follow-up. Retrospective analysis of PBF expression in PTC cases at different stages and correlate it with various clinicopathological parameters and patient survival. Subjects included 153 patients who received a thyroid operation for PTC at Chang Gung Memorial Hospital between 1991 and 2000. All patients had a complete follow-up till the end of 2010. Immunohistochemical study for PBF expression on tissue sections from tumour specimens. Bond automated machine (Leica Microsystems, Germany) with a polyclonal rabbit anti-PBF antibody (LifeSpan BioSciences, LS-C118942, Seattle, WA, USA) was used. SPSS 13.0 for Windows (SPSS Inc, Chicago, IL, USA) was used for all statistical analyses. High PBF expression was significantly correlated with age (P=0.0298), distant metastases at diagnosis (P=0.0139), tumour multicentricity (P=0.0035), TNM stage (P=0.0103), locoregional recurrence (P=0.0410) and disease-specific mortality (P=0.0064). The expression level of PBF was significantly correlated with disease-specific survival (P=0.0065). Cox regression analysis showed that age, tumour size and PBF expression were independent prognostic indicators (P=0.0097, P=0.0021 and P =0.0179). PBF expression may be a promising biomarker for prognostic and therapeutic purpose. More large-scale studies are needed to clarify its potential usefulness. Summary Background Pituitary tumour‐transforming gene (PTTG)‐binding factor (PBF), originally known as PTTG1 interacting protein (PTTG1IP), has been found to be significantly increased in well‐differentiated thyroid cancer and independently associated with early tumour recurrence. Objective To assess the prognostic significance of PBF expression in a large cohort of papillary thyroid carcinoma (PTC) patients with a long‐term follow‐up. Design and patients Retrospective analysis of PBF expression in PTC cases at different stages and correlate it with various clinicopathological parameters and patient survival. Subjects included 153 patients who received a thyroid operation for PTC at Chang Gung Memorial Hospital between 1991 and 2000. All patients had a complete follow‐up till the end of 2010. Measurements Immunohistochemical study for PBF expression on tissue sections from tumour specimens. Bond automated machine (Leica Microsystems, Germany) with a polyclonal rabbit anti‐PBF antibody (LifeSpan BioSciences, LS‐C118942, Seattle, WA, USA) was used. SPSS 13.0 for Windows (SPSS Inc, Chicago, IL, USA) was used for all statistical analyses. Results High PBF expression was significantly correlated with age (P = 0·0298), distant metastases at diagnosis (P = 0·0139), tumour multicentricity (P = 0·0035), TNM stage (P = 0·0103), locoregional recurrence (P = 0·0410) and disease‐specific mortality (P = 0·0064). The expression level of PBF was significantly correlated with disease‐specific survival (P = 0·0065). Cox regression analysis showed that age, tumour size and PBF expression were independent prognostic indicators (P = 0·0097, P = 0·0021 and P = 0·0179). Conclusion PBF expression may be a promising biomarker for prognostic and therapeutic purpose. More large‐scale studies are needed to clarify its potential usefulness. Pituitary tumour-transforming gene (PTTG)-binding factor (PBF), originally known as PTTG1 interacting protein (PTTG1IP), has been found to be significantly increased in well-differentiated thyroid cancer and independently associated with early tumour recurrence. To assess the prognostic significance of PBF expression in a large cohort of papillary thyroid carcinoma (PTC) patients with a long-term follow-up. Retrospective analysis of PBF expression in PTC cases at different stages and correlate it with various clinicopathological parameters and patient survival. Subjects included 153 patients who received a thyroid operation for PTC at Chang Gung Memorial Hospital between 1991 and 2000. All patients had a complete follow-up till the end of 2010. Immunohistochemical study for PBF expression on tissue sections from tumour specimens. Bond automated machine (Leica Microsystems, Germany) with a polyclonal rabbit anti-PBF antibody (LifeSpan BioSciences, LS-C118942, Seattle, WA, USA) was used. SPSS 13.0 for Windows (SPSS Inc, Chicago, IL, USA) was used for all statistical analyses. High PBF expression was significantly correlated with age (P = 0·0298), distant metastases at diagnosis (P = 0·0139), tumour multicentricity (P = 0·0035), TNM stage (P = 0·0103), locoregional recurrence (P = 0·0410) and disease-specific mortality (P = 0·0064). The expression level of PBF was significantly correlated with disease-specific survival (P = 0·0065). Cox regression analysis showed that age, tumour size and PBF expression were independent prognostic indicators (P = 0·0097, P = 0·0021 and P = 0·0179). PBF expression may be a promising biomarker for prognostic and therapeutic purpose. More large-scale studies are needed to clarify its potential usefulness. Summary Background Pituitary tumour-transforming gene (PTTG)-binding factor (PBF), originally known as PTTG1 interacting protein (PTTG1IP), has been found to be significantly increased in well-differentiated thyroid cancer and independently associated with early tumour recurrence. Objective To assess the prognostic significance of PBF expression in a large cohort of papillary thyroid carcinoma (PTC) patients with a long-term follow-up. Design and patients Retrospective analysis of PBF expression in PTC cases at different stages and correlate it with various clinicopathological parameters and patient survival. Subjects included 153 patients who received a thyroid operation for PTC at Chang Gung Memorial Hospital between 1991 and 2000. All patients had a complete follow-up till the end of 2010. Measurements Immunohistochemical study for PBF expression on tissue sections from tumour specimens. Bond automated machine (Leica Microsystems, Germany) with a polyclonal rabbit anti-PBF antibody (LifeSpan BioSciences, LS-C118942, Seattle, WA,USA) was used. SPSS 13.0 for Windows (SPSS Inc, Chicago, IL,USA) was used for all statistical analyses. Results High PBF expression was significantly correlated with age (P = 0·0298), distant metastases at diagnosis (P = 0·0139), tumour multicentricity (P = 0·0035), TNM stage (P = 0·0103), locoregional recurrence (P = 0·0410) and disease-specific mortality (P = 0·0064). The expression level of PBF was significantly correlated with disease-specific survival (P = 0·0065). Cox regression analysis showed that age, tumour size and PBF expression were independent prognostic indicators (P = 0·0097, P = 0·0021 and P = 0·0179). Conclusion PBF expression may be a promising biomarker for prognostic and therapeutic purpose. More large-scale studies are needed to clarify its potential usefulness. [PUBLICATION ABSTRACT] Pituitary tumour-transforming gene (PTTG)-binding factor (PBF), originally known as PTTG1 interacting protein (PTTG1IP), has been found to be significantly increased in well-differentiated thyroid cancer and independently associated with early tumour recurrence.BACKGROUNDPituitary tumour-transforming gene (PTTG)-binding factor (PBF), originally known as PTTG1 interacting protein (PTTG1IP), has been found to be significantly increased in well-differentiated thyroid cancer and independently associated with early tumour recurrence.To assess the prognostic significance of PBF expression in a large cohort of papillary thyroid carcinoma (PTC) patients with a long-term follow-up.OBJECTIVETo assess the prognostic significance of PBF expression in a large cohort of papillary thyroid carcinoma (PTC) patients with a long-term follow-up.Retrospective analysis of PBF expression in PTC cases at different stages and correlate it with various clinicopathological parameters and patient survival. Subjects included 153 patients who received a thyroid operation for PTC at Chang Gung Memorial Hospital between 1991 and 2000. All patients had a complete follow-up till the end of 2010.DESIGN AND PATIENTSRetrospective analysis of PBF expression in PTC cases at different stages and correlate it with various clinicopathological parameters and patient survival. Subjects included 153 patients who received a thyroid operation for PTC at Chang Gung Memorial Hospital between 1991 and 2000. All patients had a complete follow-up till the end of 2010.Immunohistochemical study for PBF expression on tissue sections from tumour specimens. Bond automated machine (Leica Microsystems, Germany) with a polyclonal rabbit anti-PBF antibody (LifeSpan BioSciences, LS-C118942, Seattle, WA, USA) was used. SPSS 13.0 for Windows (SPSS Inc, Chicago, IL, USA) was used for all statistical analyses.MEASUREMENTSImmunohistochemical study for PBF expression on tissue sections from tumour specimens. Bond automated machine (Leica Microsystems, Germany) with a polyclonal rabbit anti-PBF antibody (LifeSpan BioSciences, LS-C118942, Seattle, WA, USA) was used. SPSS 13.0 for Windows (SPSS Inc, Chicago, IL, USA) was used for all statistical analyses.High PBF expression was significantly correlated with age (P = 0·0298), distant metastases at diagnosis (P = 0·0139), tumour multicentricity (P = 0·0035), TNM stage (P = 0·0103), locoregional recurrence (P = 0·0410) and disease-specific mortality (P = 0·0064). The expression level of PBF was significantly correlated with disease-specific survival (P = 0·0065). Cox regression analysis showed that age, tumour size and PBF expression were independent prognostic indicators (P = 0·0097, P = 0·0021 and P = 0·0179).RESULTSHigh PBF expression was significantly correlated with age (P = 0·0298), distant metastases at diagnosis (P = 0·0139), tumour multicentricity (P = 0·0035), TNM stage (P = 0·0103), locoregional recurrence (P = 0·0410) and disease-specific mortality (P = 0·0064). The expression level of PBF was significantly correlated with disease-specific survival (P = 0·0065). Cox regression analysis showed that age, tumour size and PBF expression were independent prognostic indicators (P = 0·0097, P = 0·0021 and P = 0·0179).PBF expression may be a promising biomarker for prognostic and therapeutic purpose. More large-scale studies are needed to clarify its potential usefulness.CONCLUSIONPBF expression may be a promising biomarker for prognostic and therapeutic purpose. More large-scale studies are needed to clarify its potential usefulness. |
| Author | Chang, Yu-Sun Sun, Jui-Hung Hsueh, Chuen Chao, Tzu-Chieh Yu, Jau-Song Kuo, Shau-Yun Lin, Jen-Der Jung, Shih-Ming Hsueh, Swei Tseng, Ngan-Ming Ueng, Shir-Hwa |
| Author_xml | – sequence: 1 givenname: Chuen surname: Hsueh fullname: Hsueh, Chuen email: ch9211@adm.cgmh.org.tw organization: Department of Pathology, Chang Gung Memorial Hospital, Linko, Chang Gung University College of Medicine, Taoyuan, Taiwan – sequence: 2 givenname: Jen-Der surname: Lin fullname: Lin, Jen-Der organization: Department of Internal Medicine, Chang Gung Memorial Hospital, Linko, Chang Gung University College of Medicine, Taoyuan, Taiwan – sequence: 3 givenname: Yu-Sun surname: Chang fullname: Chang, Yu-Sun organization: Chang Gung Molecular Medicine Research Center and Graduate Institute of Basic Medical Sciences, Chang Gung University College of Medicine, Taoyuan, Taiwan – sequence: 4 givenname: Swei surname: Hsueh fullname: Hsueh, Swei organization: Department of Pathology, Chang Gung Memorial Hospital, Linko, Chang Gung University College of Medicine, Taoyuan, Taiwan – sequence: 5 givenname: Tzu-Chieh surname: Chao fullname: Chao, Tzu-Chieh organization: Department of Surgery, Chang Gung Memorial Hospital, Linko, Chang Gung University College of Medicine, Taoyuan, Taiwan – sequence: 6 givenname: Jau-Song surname: Yu fullname: Yu, Jau-Song organization: Chang Gung Molecular Medicine Research Center and Graduate Institute of Basic Medical Sciences, Chang Gung University College of Medicine, Taoyuan, Taiwan – sequence: 7 givenname: Shih-Ming surname: Jung fullname: Jung, Shih-Ming organization: Department of Pathology, Chang Gung Memorial Hospital, Linko, Chang Gung University College of Medicine, Taoyuan, Taiwan – sequence: 8 givenname: Ngan-Ming surname: Tseng fullname: Tseng, Ngan-Ming organization: Department of Radiation Oncology, Chang Gung Memorial Hospital, Linko, Chang Gung University College of Medicine, Taoyuan, Taiwan – sequence: 9 givenname: Jui-Hung surname: Sun fullname: Sun, Jui-Hung organization: Department of Internal Medicine, Chang Gung Memorial Hospital, Linko, Chang Gung University College of Medicine, Taoyuan, Taiwan – sequence: 10 givenname: Shau-Yun surname: Kuo fullname: Kuo, Shau-Yun organization: Chang Gung Molecular Medicine Research Center and Graduate Institute of Basic Medical Sciences, Chang Gung University College of Medicine, Taoyuan, Taiwan – sequence: 11 givenname: Shir-Hwa surname: Ueng fullname: Ueng, Shir-Hwa organization: Department of Pathology, Chang Gung Memorial Hospital, Linko, Chang Gung University College of Medicine, Taoyuan, Taiwan |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26803140$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22888961$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkl9rFDEUxYNU7Lb64BeQARHah2nzZ5LMPNal3YrLWlDRt5C5k1lTZ5IxmcEu-OFNu9sKBTUvIfA7l5tzzgHac94ZhF4SfELSOQXjTgjFWD5BM8IEzykVfA_NMMM4x0IU--ggxmuMMS-xfIb2KS3LshJkhn5dBb92Po4WsmjXzrYWtAOT-TYb7DjZUYdNNk69n0I-Bu1i60Nv3TpbG2fy2rrm9tFqGH3Ijq7eXhxn5mYIJkbrXWZdNujBdt3dlG-b4G2TgQ5gne_1c_S01V00L3b3Ifp8cf5pfpkvPyzezc-WORS8kDltCwaYNJIKxqtCSFFxbgAKoSsQ0FLDgLYCJK25rOuG0gpwUzXJippAw9ghOtrOHYL_MZk4qt5GMGkrZ_wUFZG8pKwqK_p_lEqWXE1rJPT1I_Q6meTSRxThtOKiIlIk6tWOmureNGoItk9mqPsIEvBmB-gIumuTx2DjH06UmJECJ-54y0HwMQbTPiAEq9saqFQDdVeDxJ4-YiEFOaZEUoS2-5fip-3M5u-j1fx8da_ItwobR3PzoNDhuxKSSa6-rBZq-fH9V3m5WCnKfgN3ldIq |
| CODEN | CLECAP |
| CitedBy_id | crossref_primary_10_1007_s13402_016_0277_5 crossref_primary_10_3390_cancers14194876 crossref_primary_10_1002_mc_22254 crossref_primary_10_1089_gtmb_2013_0447 crossref_primary_10_3389_fimmu_2023_1254911 crossref_primary_10_1089_dna_2022_0243 crossref_primary_10_1186_s12885_017_3694_6 crossref_primary_10_1111_and_12283 crossref_primary_10_1515_med_2019_0086 crossref_primary_10_1210_jc_2012_3640 crossref_primary_10_1530_ERC_16_0340 crossref_primary_10_1111_cen_12421 crossref_primary_10_3390_cancers13020212 crossref_primary_10_1155_2019_9421079 crossref_primary_10_3389_fendo_2019_00619 crossref_primary_10_3892_ol_2019_10400 crossref_primary_10_1210_en_2013_1646 crossref_primary_10_2174_0929866526666190722145449 crossref_primary_10_1371_journal_pone_0090396 |
| Cites_doi | 10.1210/er.2006-0042 10.1046/j.1365-2265.2003.01598.x 10.1210/jc.2005-2532 10.1089/thy.2009.0133 10.1210/jc.86.10.5025 10.1210/er.2007-0007 10.1111/j.1365-2559.2006.02412.x 10.1126/science.285.5426.418 10.1038/sj.onc.1210221 10.1007/s00268-002-6612-1 10.1158/0008-5472.CAN-09-3531 10.1210/jc.2005-1826 10.1210/jc.2002-021113 10.1210/mend.11.4.9911 10.1016/S0968-0004(99)01416-4 10.1210/jc.2002-020309 10.1001/jama.295.18.2164 10.1158/0008-5472.CAN-11-0720 10.1210/jc.86.2.867 10.1210/jcem.86.4.7407 10.1245/s10434-009-0565-7 10.1074/jbc.M910105199 10.1210/mend.13.1.0225 10.1006/geno.1998.5217 10.1242/jcs.045427 10.1210/jc.2005-0523 |
| ContentType | Journal Article |
| Copyright | 2012 Blackwell Publishing Ltd 2014 INIST-CNRS 2012 Blackwell Publishing Ltd. Copyright © 2013 Blackwell Publishing Ltd |
| Copyright_xml | – notice: 2012 Blackwell Publishing Ltd – notice: 2014 INIST-CNRS – notice: 2012 Blackwell Publishing Ltd. – notice: Copyright © 2013 Blackwell Publishing Ltd |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP K9. NAPCQ 7X8 8FD FR3 P64 RC3 |
| DOI | 10.1111/cen.12007 |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Calcium & Calcified Tissue Abstracts MEDLINE - Academic Genetics Abstracts Engineering Research Database Technology Research Database Biotechnology and BioEngineering Abstracts |
| DatabaseTitleList | Genetics Abstracts MEDLINE ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2265 |
| EndPage | 309 |
| ExternalDocumentID | 3317531161 22888961 26803140 10_1111_cen_12007 CEN12007 ark_67375_WNG_LSKX7HGN_2 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Ministry of Education funderid: EMRPD1A0391 |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 08P 0R~ 10A 1OB 1OC 29B 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AAQQT AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K REN RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7QP K9. NAPCQ 7X8 8FD FR3 P64 RC3 |
| ID | FETCH-LOGICAL-c4547-2f43c01d7263594676955ecc46a9c6cf2e3c2f6c72b57bbd229c0d9d136b1cd33 |
| IEDL.DBID | DR2 |
| ISSN | 0300-0664 1365-2265 |
| IngestDate | Tue Aug 05 10:41:18 EDT 2025 Thu Jul 10 23:06:30 EDT 2025 Wed Aug 13 04:19:53 EDT 2025 Wed Feb 19 01:51:47 EST 2025 Mon Jul 21 09:12:18 EDT 2025 Tue Jul 01 01:33:09 EDT 2025 Thu Apr 24 22:57:05 EDT 2025 Wed Jan 22 16:57:53 EST 2025 Wed Oct 30 09:53:29 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Endocrinopathy Binding Endocrine gland Prognosis Thyroid diseases Pituitary gland Malignant tumor Gene expression Papillary thyroid carcinoma Endocrinology Cancer |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 2012 Blackwell Publishing Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4547-2f43c01d7263594676955ecc46a9c6cf2e3c2f6c72b57bbd229c0d9d136b1cd33 |
| Notes | ArticleID:CEN12007 ark:/67375/WNG-LSKX7HGN-2 Ministry of Education - No. EMRPD1A0391 istex:F8C22626F5B134679ECBF5F261935606D70FA770 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 22888961 |
| PQID | 1529569176 |
| PQPubID | 36523 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_1758239892 proquest_miscellaneous_1273300594 proquest_journals_1529569176 pubmed_primary_22888961 pascalfrancis_primary_26803140 crossref_primary_10_1111_cen_12007 crossref_citationtrail_10_1111_cen_12007 wiley_primary_10_1111_cen_12007_CEN12007 istex_primary_ark_67375_WNG_LSKX7HGN_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | February 2013 |
| PublicationDateYYYYMMDD | 2013-02-01 |
| PublicationDate_xml | – month: 02 year: 2013 text: February 2013 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford – name: England |
| PublicationTitle | Clinical endocrinology (Oxford) |
| PublicationTitleAlternate | Clin Endocrinol |
| PublicationYear | 2013 |
| Publisher | Blackwell Publishing Ltd Blackwell Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell – name: Wiley Subscription Services, Inc |
| References | Mazzaferri, E.L. & Kloos, R.T. (2001) Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 86, 1447-1463. Read, M.L., Lewy, G.D., Fong, J.C. et al. (2011) Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment. Cancer Research, 71, 6153-6164. Yaspo, M.L., Aaltonen, J., Horelli-Kuitunen, N. et al. (1998) Cloning of a novel human putative type Ia integral membrane protein mapping to 21q22.3. Genomics, 49, 133-136. McCabe, C.J., Boelaert, K., Tannahill, L.A. et al. (2002) Vascular endothelial growth factor (VEGF), its receptor KDR and pituitary tumor transforming gene in pituitary tumors. The Journal of Clinical Endocrinology and Metabolism, 87, 4238-4244. Bork, P., Doerks, T., Springer, T.A. et al. (1999) Domains in plexins: links to integrins and transcription factors. Trends in Biochemical Sciences, 24, 261-263. Lin, J.D., Chao, T.C., Hsueh, C. et al. (2009) High recurrent rate of multi-centric papillary thyroid carcinoma. Annals of Surgical Oncology, 16, 2609-2616. Heaney, A.P., Nelson, V., Fernando, M. et al. (2001) Transforming events in thyroid tumorigenesis and their association with follicular lesions. Journal of Clinical Endocrinology and Metabolism, 86, 5025-5032. Smith, V.E., Read, M.L., Turnell, A.S. et al. (2009) A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. Journal of Cell Science, 122, 3393-3402. Vlotides, G., Eigler, T. & Melmed, S. (2007) Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocrine Reviews, 28, 165-186. Lin, J.D., Hsueh, C. & Chao, T.C. (2009) Early recurrence papillary and follicular thyroid carcinoma predicts a worse outcome. Thyroid, 19, 1053-1058. Xing, M. (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews, 28, 742-762. Zou, H., McGarry, T.J., Bernal, T. et al. (1999) Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science, 285, 418-422. Kirkegaard, T., Edwards, J., Tovey, S. et al. (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology, 48, 787-794. Watkins, R.J., Read, M.L., Smith, V.E. et al. (2010) Pituitary tumor transforming gene binding factor: a new gene in breast cancer. Cancer Research, 70, 3739-3749. Boelaert, K., McCabe, C.J., Tannahill, L.A. et al. (2003) Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 88, 2341-2347. Kim, D.S., Franklyn, J.A., Stratford, A.L. et al. (2006) Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 91, 1119-1128. Davies, L. & Welch, H.G. (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association, 295, 2164-2167. Chien, W. & Pei, L. (2000) A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product. Journal of Biological Chemistry, 275, 19422-19427. Zhang, X, Horwitz, G.A., Prezant, T.R. et al. (1999b) Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Molecular Endocrinology 13, 156-166. Pei, L. & Melmed, S. (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Molecular Endocrinology, 11, 433-441. McCabe, C.J., Khaira, J.S., Boelaert, K. et al. (2003) Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clincal Endocrinology (Oxford), 58, 141-150. Saez, C., Martinez-Brocca, M.A., Castilla, C. et al. (2006) Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 91, 1404-1409. Ishikawa, H., Heaney, A.P., Yu, R. et al. (2001) Human pituitary tumor-transforming gene induces angiogenesis. Journal of Clinical Endocrinology and Metabolism, 86, 867-874. Hay, I.D., Thompson, G.B., Grant, C.S. et al. (2002) Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World Journal of Surgery, 26, 879-885. Boelaert, K., Smith, V.E., Stratford, A.L. et al. (2007) PTTG and PBF repress the human sodium iodide symporter. Oncogene, 26, 4344-4356. Stratford, A.L., Boelaert, K., Tannahill, L.A. et al. (2005) Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. Journal of Clinical Endocrinology and Metabolism, 90, 4341-4349. 2007; 28 1998; 49 1999b; 13 2002; 26 2006; 91 1997; 11 2005; 90 2011; 71 2002; 87 2006; 48 2006; 295 1999; 285 1999; 24 2003; 58 2009; 122 2000; 275 2004 2010; 70 2009; 19 2009; 16 2001; 86 2007; 26 2003; 88 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_13_1 e_1_2_7_12_1 LiVolsi V.A. (e_1_2_7_14_1) 2004 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_27_1 e_1_2_7_28_1 Zhang X (e_1_2_7_26_1) 1999; 13 e_1_2_7_25_1 e_1_2_7_24_1 e_1_2_7_23_1 e_1_2_7_22_1 e_1_2_7_21_1 e_1_2_7_20_1 |
| References_xml | – reference: Yaspo, M.L., Aaltonen, J., Horelli-Kuitunen, N. et al. (1998) Cloning of a novel human putative type Ia integral membrane protein mapping to 21q22.3. Genomics, 49, 133-136. – reference: Smith, V.E., Read, M.L., Turnell, A.S. et al. (2009) A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. Journal of Cell Science, 122, 3393-3402. – reference: Zhang, X, Horwitz, G.A., Prezant, T.R. et al. (1999b) Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Molecular Endocrinology 13, 156-166. – reference: Watkins, R.J., Read, M.L., Smith, V.E. et al. (2010) Pituitary tumor transforming gene binding factor: a new gene in breast cancer. Cancer Research, 70, 3739-3749. – reference: Xing, M. (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews, 28, 742-762. – reference: Zou, H., McGarry, T.J., Bernal, T. et al. (1999) Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science, 285, 418-422. – reference: Hay, I.D., Thompson, G.B., Grant, C.S. et al. (2002) Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World Journal of Surgery, 26, 879-885. – reference: Kim, D.S., Franklyn, J.A., Stratford, A.L. et al. (2006) Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 91, 1119-1128. – reference: Davies, L. & Welch, H.G. (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association, 295, 2164-2167. – reference: Lin, J.D., Hsueh, C. & Chao, T.C. (2009) Early recurrence papillary and follicular thyroid carcinoma predicts a worse outcome. Thyroid, 19, 1053-1058. – reference: Bork, P., Doerks, T., Springer, T.A. et al. (1999) Domains in plexins: links to integrins and transcription factors. Trends in Biochemical Sciences, 24, 261-263. – reference: Boelaert, K., Smith, V.E., Stratford, A.L. et al. (2007) PTTG and PBF repress the human sodium iodide symporter. Oncogene, 26, 4344-4356. – reference: Ishikawa, H., Heaney, A.P., Yu, R. et al. (2001) Human pituitary tumor-transforming gene induces angiogenesis. Journal of Clinical Endocrinology and Metabolism, 86, 867-874. – reference: Heaney, A.P., Nelson, V., Fernando, M. et al. (2001) Transforming events in thyroid tumorigenesis and their association with follicular lesions. Journal of Clinical Endocrinology and Metabolism, 86, 5025-5032. – reference: Lin, J.D., Chao, T.C., Hsueh, C. et al. (2009) High recurrent rate of multi-centric papillary thyroid carcinoma. Annals of Surgical Oncology, 16, 2609-2616. – reference: Mazzaferri, E.L. & Kloos, R.T. (2001) Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 86, 1447-1463. – reference: Pei, L. & Melmed, S. (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Molecular Endocrinology, 11, 433-441. – reference: McCabe, C.J., Boelaert, K., Tannahill, L.A. et al. (2002) Vascular endothelial growth factor (VEGF), its receptor KDR and pituitary tumor transforming gene in pituitary tumors. The Journal of Clinical Endocrinology and Metabolism, 87, 4238-4244. – reference: Kirkegaard, T., Edwards, J., Tovey, S. et al. (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology, 48, 787-794. – reference: Vlotides, G., Eigler, T. & Melmed, S. (2007) Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocrine Reviews, 28, 165-186. – reference: McCabe, C.J., Khaira, J.S., Boelaert, K. et al. (2003) Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clincal Endocrinology (Oxford), 58, 141-150. – reference: Read, M.L., Lewy, G.D., Fong, J.C. et al. (2011) Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment. Cancer Research, 71, 6153-6164. – reference: Stratford, A.L., Boelaert, K., Tannahill, L.A. et al. (2005) Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. Journal of Clinical Endocrinology and Metabolism, 90, 4341-4349. – reference: Chien, W. & Pei, L. (2000) A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product. Journal of Biological Chemistry, 275, 19422-19427. – reference: Boelaert, K., McCabe, C.J., Tannahill, L.A. et al. (2003) Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 88, 2341-2347. – reference: Saez, C., Martinez-Brocca, M.A., Castilla, C. et al. (2006) Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 91, 1404-1409. – volume: 86 start-page: 867 year: 2001 end-page: 874 article-title: Human pituitary tumor‐transforming gene induces angiogenesis publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 295 start-page: 2164 year: 2006 end-page: 2167 article-title: Increasing incidence of thyroid cancer in the United States, 1973–2002 publication-title: Journal of the American Medical Association – volume: 88 start-page: 2341 year: 2003 end-page: 2347 article-title: Pituitary tumor transforming gene and fibroblast growth factor‐2 expression: potential prognostic indicators in differentiated thyroid cancer publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 49 start-page: 133 year: 1998 end-page: 136 article-title: Cloning of a novel human putative type Ia integral membrane protein mapping to 21q22.3 publication-title: Genomics – volume: 24 start-page: 261 year: 1999 end-page: 263 article-title: Domains in plexins: links to integrins and transcription factors publication-title: Trends in Biochemical Sciences – volume: 28 start-page: 742 year: 2007 end-page: 762 article-title: BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications publication-title: Endocrine Reviews – volume: 11 start-page: 433 year: 1997 end-page: 441 article-title: Isolation and characterization of a pituitary tumor‐transforming gene (PTTG) publication-title: Molecular Endocrinology – volume: 26 start-page: 4344 year: 2007 end-page: 4356 article-title: PTTG and PBF repress the human sodium iodide symporter publication-title: Oncogene – start-page: 57 year: 2004 end-page: 66 article-title: Papillary carcinoma – volume: 87 start-page: 4238 year: 2002 end-page: 4244 article-title: Vascular endothelial growth factor (VEGF), its receptor KDR and pituitary tumor transforming gene in pituitary tumors publication-title: The Journal of Clinical Endocrinology and Metabolism – volume: 86 start-page: 1447 year: 2001 end-page: 1463 article-title: Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 91 start-page: 1404 year: 2006 end-page: 1409 article-title: Prognostic significance of human pituitary tumor‐transforming gene immunohistochemical expression in differentiated thyroid cancer publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 16 start-page: 2609 year: 2009 end-page: 2616 article-title: High recurrent rate of multi‐centric papillary thyroid carcinoma publication-title: Annals of Surgical Oncology – volume: 19 start-page: 1053 year: 2009 end-page: 1058 article-title: Early recurrence papillary and follicular thyroid carcinoma predicts a worse outcome publication-title: Thyroid – volume: 122 start-page: 3393 year: 2009 end-page: 3402 article-title: A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer publication-title: Journal of Cell Science – volume: 13 start-page: 156 year: 1999b end-page: 166 article-title: Structure, expression, and function of human pituitary tumor‐transforming gene (PTTG) publication-title: Molecular Endocrinology – volume: 90 start-page: 4341 year: 2005 end-page: 4349 article-title: Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 70 start-page: 3739 year: 2010 end-page: 3749 article-title: Pituitary tumor transforming gene binding factor: a new gene in breast cancer publication-title: Cancer Research – volume: 91 start-page: 1119 year: 2006 end-page: 1128 article-title: Pituitary tumor‐transforming gene regulates multiple downstream angiogenic genes in thyroid cancer publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 71 start-page: 6153 year: 2011 end-page: 6164 article-title: Proto‐oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment publication-title: Cancer Research – volume: 285 start-page: 418 year: 1999 end-page: 422 article-title: Identification of a vertebrate sister‐chromatid separation inhibitor involved in transformation and tumorigenesis publication-title: Science – volume: 26 start-page: 879 year: 2002 end-page: 885 article-title: Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long‐term outcome in 2444 consecutively treated patients publication-title: World Journal of Surgery – volume: 275 start-page: 19422 year: 2000 end-page: 19427 article-title: A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor‐transforming gene product publication-title: Journal of Biological Chemistry – volume: 48 start-page: 787 year: 2006 end-page: 794 article-title: Observer variation in immunohistochemical analysis of protein expression, time for a change? publication-title: Histopathology – volume: 58 start-page: 141 year: 2003 end-page: 150 article-title: Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor‐2 (FGF‐2) in human pituitary adenomas: relationships to clinical tumour behaviour publication-title: Clincal Endocrinology (Oxford) – volume: 86 start-page: 5025 year: 2001 end-page: 5032 article-title: Transforming events in thyroid tumorigenesis and their association with follicular lesions publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 28 start-page: 165 year: 2007 end-page: 186 article-title: Pituitary tumor‐transforming gene: physiology and implications for tumorigenesis publication-title: Endocrine Reviews – ident: e_1_2_7_11_1 doi: 10.1210/er.2006-0042 – ident: e_1_2_7_12_1 doi: 10.1046/j.1365-2265.2003.01598.x – ident: e_1_2_7_21_1 doi: 10.1210/jc.2005-2532 – ident: e_1_2_7_17_1 doi: 10.1089/thy.2009.0133 – start-page: 57 volume-title: World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of Endocrine Organs year: 2004 ident: e_1_2_7_14_1 – ident: e_1_2_7_22_1 doi: 10.1210/jc.86.10.5025 – ident: e_1_2_7_5_1 doi: 10.1210/er.2007-0007 – ident: e_1_2_7_15_1 doi: 10.1111/j.1365-2559.2006.02412.x – ident: e_1_2_7_9_1 doi: 10.1126/science.285.5426.418 – ident: e_1_2_7_10_1 doi: 10.1038/sj.onc.1210221 – ident: e_1_2_7_4_1 doi: 10.1007/s00268-002-6612-1 – ident: e_1_2_7_19_1 doi: 10.1158/0008-5472.CAN-09-3531 – ident: e_1_2_7_24_1 doi: 10.1210/jc.2005-1826 – ident: e_1_2_7_20_1 doi: 10.1210/jc.2002-021113 – ident: e_1_2_7_8_1 doi: 10.1210/mend.11.4.9911 – ident: e_1_2_7_28_1 doi: 10.1016/S0968-0004(99)01416-4 – ident: e_1_2_7_23_1 doi: 10.1210/jc.2002-020309 – ident: e_1_2_7_2_1 doi: 10.1001/jama.295.18.2164 – ident: e_1_2_7_27_1 doi: 10.1158/0008-5472.CAN-11-0720 – ident: e_1_2_7_25_1 doi: 10.1210/jc.86.2.867 – ident: e_1_2_7_3_1 doi: 10.1210/jcem.86.4.7407 – ident: e_1_2_7_16_1 doi: 10.1245/s10434-009-0565-7 – ident: e_1_2_7_6_1 doi: 10.1074/jbc.M910105199 – volume: 13 start-page: 156 year: 1999 ident: e_1_2_7_26_1 article-title: Structure, expression, and function of human pituitary tumor‐transforming gene (PTTG) publication-title: Molecular Endocrinology doi: 10.1210/mend.13.1.0225 – ident: e_1_2_7_7_1 doi: 10.1006/geno.1998.5217 – ident: e_1_2_7_18_1 doi: 10.1242/jcs.045427 – ident: e_1_2_7_13_1 doi: 10.1210/jc.2005-0523 |
| SSID | ssj0005807 |
| Score | 2.1813438 |
| Snippet | Summary
Background
Pituitary tumour‐transforming gene (PTTG)‐binding factor (PBF), originally known as PTTG1 interacting protein (PTTG1IP), has been found to... Pituitary tumour-transforming gene (PTTG)-binding factor (PBF), originally known as PTTG1 interacting protein (PTTG1IP), has been found to be significantly... Summary Background Pituitary tumour-transforming gene (PTTG)-binding factor (PBF), originally known as PTTG1 interacting protein (PTTG1IP), has been found to... |
| SourceID | proquest pubmed pascalfrancis crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 303 |
| SubjectTerms | Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Carcinoma, Papillary - metabolism Carcinoma, Papillary - surgery Endocrinopathies Female Fundamental and applied biological sciences. Psychology Gene Expression Regulation, Neoplastic - physiology Humans Male Malignant tumors Medical sciences Membrane Proteins - genetics Membrane Proteins - metabolism Middle Aged Non tumoral diseases. Target tissue resistance. Benign neoplasms Prognosis Thyroid Neoplasms - metabolism Thyroid Neoplasms - surgery Thyroid. Thyroid axis (diseases) Vertebrates: endocrinology Young Adult |
| Title | Prognostic significance of pituitary tumour-transforming gene-binding factor (PBF) expression in papillary thyroid carcinoma |
| URI | https://api.istex.fr/ark:/67375/WNG-LSKX7HGN-2/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcen.12007 https://www.ncbi.nlm.nih.gov/pubmed/22888961 https://www.proquest.com/docview/1529569176 https://www.proquest.com/docview/1273300594 https://www.proquest.com/docview/1758239892 |
| Volume | 78 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIiEuvKGBUhmEUDlktXEcJxYnqLpdAV1VQMUekCLbiUVUmqx2E6lw6k_gN_JLmHEeZVFBiFu0mTw8noln1t98Q8hTk4SGSxX5DDMdbhj3peS5r3Axz7CMNsB658OZmB7z1_NovkFe9LUwLT_E8Icbeob7XqODK736xclNXo6CrpIcsVoYEL27oI6KulLpECunheAdqxCieIYr19aiK6jWM8RGqhWox7Z9LS4LPNfjWLcQTW6QT_0QWvzJyaip9ch8-43d8T_HeJNc7wJU-rK1qFtkIy9vk6uH3Rb8HXJ-tKwQnAenKYI_EGqElkMrSxdF3RQ1PI7WzSnc6Mf597oPjGGJpGCsOfymC1dKQ9teP3T36NXkOc3POkhuSYuSLtQC2yHhnT5_XVZFRg02PSqrU3WXHE_2P-xN_a6Ng2-QLcxnlocGpjxG3hvJEVMbRWA5XChphLEsDw2zwsRMR7HWGWPSjDOZwaTqwGRheI9sllWZbxFqpcm0tpDT2YxnzGobGezlHo0NCzIVe2S3n9DUdBzn2GrjS9rnOqDR1GnUI08G0UVL7HGZ0DNnFYOEWp4gEi6O0o-zg_Tt-zfzeHowS5lHdtbMZriAiQQbBIw9st3bUdp9JVZpgLusAhJm4ZHHw2nwb9y0UWVeNSAD8WXoWHX-IgNJH_I4SniP-62NXrwAS5JEigBU4yztz4NN9_Zn7uDBv4s-JNeY6w-C-J5tslkvm_wRRGm13nHu-BNZlDpV |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqVgIuvB-BUgxCqByy2jiOE0tcoOp2obtRBa3YC7JiOxZRabLaZqXCqT-B38gvweM8yqKCELcomTw8mYln4pnvQ-i5SkJFeRb5BDIdqgj1Oae5n8FkrqGNNoB-52nKxkf03SyaraFXXS9Mgw_R_3ADz3Dfa3Bw-CH9i5ervBwETSv5BjB6u4Tq_QV4VNQ2S4fQO80YbXGFoI6nP3VlNtoAxZ5BdWR2ahVkGmaLy0LP1UjWTUWjG-hTN4imAuV4sKzlQH37Dd_xf0d5E11vY1T8ujGqW2gtL2-jK9N2Ff4OOj9YVFCfZw9jqP-AaiMwHlwZPC_qZVHb--F6eWIv9OP8e93FxnaWxNZec7tPFq6bBjd0P3j74M3oJc7P2qrcEhclnmdzYESCK33-uqgKjRXwHpXVSXYXHY12D3fGfsvk4CsADPOJoaGybz0G6BtOoaw2iqzxUJZxxZQheaiIYSomMoql1IRwNdRcByGTgdJheA-tl1WZP0DYcKWlNDatM5pqYqSJFNC5R0NFAp3FHtru3qhQLcw5sG18EV26YzUqnEY99KwXnTfYHpcJvXBm0Utki2Mohosj8THdE5MP-7N4vJcK4qGtFbvpTyAsAY6AoYc2O0MS7YfiVASw0Mpszsw89LQ_bF0c1m2yMq-WVsaGmKED1vmLjM37AMqR2-e43xjpxQOQJEk4C6xqnKn9ebBiZzd1Gw__XfQJujo-nE7E5G26_whdI44uBMp9NtF6vVjmj23QVsst55s_AcysPnA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELWqVqp44X4JlGIQQuUhq43jOIl4grbbhbbRCqjYh0pWbMciKk2ibSIVnvoJfCNfgse5lEUFId5Wm0k2nhzHM-szZxB6LiNf0jgNXAKZDpWEunFMMzeFxVxBGa0H9c6HCZse0XfzYL6CXvW1MK0-xPCHG8wM-76GCV4p_cskl1kx8tpK8jXKxhFAeuf9pXZU0NVK-1A6zRjtZIWAxjOcurQYrYFfz4EcmZ4Z_-i2scVVkedyIGtXoskNdNyPoSWgnIyaWozkt9_kHf9zkDfR9S5Cxa9bSN1CK1lxG60fdnvwd9DFbFECO88cxsD-AK4RQAeXGld53eS1-TlcN6fmQj8uvtd9ZGzWSGzQmpnvRG5raXDb7Advzd5MXuLsvOPkFjgvcJVW0A8JrvT566LMFZbQ9agoT9O76Giy-3F76nZ9HFwJcmEu0dSX5pmHIHwTUyDVBoGBDmVpLJnUJPMl0UyGRAShEIqQWI5VrDyfCU8q37-HVouyyB4grGOphNAmqdOKKqKFDiQ0cw_GkngqDR201T9QLjuRc-i18YX3yY7xKLceddCzwbRqlT2uMnphUTFYpIsToMKFAf-U7PGDD_vzcLqXcOKgzSXYDCcQFkGHgLGDNnoc8e41ccY92GZlJmNmDno6HDYTHHZt0iIrG2NjAkzfyur8xcZkfSDkGJv7uN9i9PIGSBRFMfOMayzS_jxYvr2b2A8P_930CVqf7Uz4wdtk_xG6RmyvEOD6bKDVetFkj03EVotNOzN_Ag0mPSg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+significance+of+pituitary+tumour-transforming+gene-binding+factor+%28PBF%29+expression+in+papillary+thyroid+carcinoma&rft.jtitle=Clinical+endocrinology+%28Oxford%29&rft.au=Hsueh%2C+Chuen&rft.au=Lin%2C+Jen-Der&rft.au=Chang%2C+Yu-Sun&rft.au=Hsueh%2C+Swei&rft.date=2013-02-01&rft.issn=0300-0664&rft.eissn=1365-2265&rft.volume=78&rft.issue=2&rft.spage=303&rft.epage=309&rft_id=info:doi/10.1111%2Fcen.12007&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-0664&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-0664&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-0664&client=summon |